SCHEMBL4091668

SCHEMBL4091668

N#Cc1c[nH]c(C(=O)C(Cl)(Cl)Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
HPGD P15428 2/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
CSF1R P07333 5/20 0.39
NTRK1 P04629 1/20 0.32
KIT P10721 1/20 0.32
AXL P30530 1/20 0.32
FLT3 P36888 1/20 0.32
GSK3B P49841 2/20 0.31
GPR35 Q9HC97 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9149351 0.84 MLYCD (0.39) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL1857408 0.79 SMN1; SMN2 (0.46) GAAPKMCSF1RNTRK1KIT
SCHEMBL8986703 0.77 CCNC (0.43) ALDH1A1KMT2AL3MBTL1PKMCSF1R
SCHEMBL1075092 0.77 CSF1R (0.41) ALDH1A1CSF1RNTRK1KITAXL
SCHEMBL276286 0.75 ALDH1A1 (0.60) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL14393872 0.74 KMT2A (0.58) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL1518124 0.73 ALDH1A1 (0.53) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL2513855 0.73 ALDH1A1 (0.51) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL13505930 0.73 ALDH1A1 (0.51) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL3766521 0.73 BAZ2B (0.50) ALDH1A1MEN1KMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMA INC (US) 2026-03-05 US disclosed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
US-20160297830-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES GALAPAGOS NV (BE) 2016-10-13 US disclosed
US-20090203737-A1 Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors ADDEX PHARMA SA (CH) 2009-08-13 US disclosed
EP-1912979-A2 PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2008-04-23 EP disclosed
WO-2006123257-A2 PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO disclosed
EP-0596204-B1 Pyrrole thiocarboxamide insecticidal and acaricidal agents AMERICAN CYANAMID CO (US) 1996-06-26 EP disclosed
US-5389669-A Inhibiting the insect growth by applying a pesticides AMERICAN CYANAMID COMPANY (US) 1995-02-14 US disclosed
EP-0431305-B1 Process for the preparation of molluscicidal 2,4,5-tribromopyrrole-3-carbonitrile compounds AMERICAN CYANAMID CO (US) 1995-01-25 EP disclosed
EP-0596204-A1 Pyrrole thiocarboxamide insecticidal and acaricidal agents AMERICAN CYANAMID COMPANY (US) 1994-05-11 EP disclosed
US-5286742-A Agriculture AMERICAN CYANAMID COMPANY (US) 1994-02-15 US disclosed
EP-0431305-A1 Process for the preparation of molluscicidal 2,4,5-tribromopyrrole-3-carbonitrile compounds AMERICAN CYANAMID COMPANY (US) 1991-06-12 EP disclosed
US-5008403-A Deacylative bromination process for the preparation of molluscicidal 2,4,5-tribromopyrrole-3-carbonitrile compounds AMERICAN CYANAMID COMPANY (US) 1991-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C9, SSB, C1S ALDH1A1 3835/4885HPGD 4023/4885MEN1 498/4885
US-20160297830-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES POLR2E, POLB, POLI ALDH1A1 2389/4885HPGD 1539/4885MEN1 3737/4885
US-20090203737-A1 Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors GRM5, GRIK5, GRM2 ALDH1A1 4261/4885HPGD 2812/4885MEN1 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.